Polymorphic Variation in Glutathione-S-transferase Genes and Risk of Chronic Myeloid Leukaemia in the Kashmiri Population

Bhat, G. A.; Bhat, Ashaqullah; Wani, Aadil; Sadiq, Nida; Samoon, Jeelani; Kaur, Rajinder; Masood, Akbar; Ganai, Bashir Ahmad

doi:10.7314/apjcp.2012.13.1.069

Cited by 31 publications

(30 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These findings are consistent with previous association studies that demonstrated GSTM1/null and GSTP1/GG are predisposing factors to CML susceptibility (Bănescu et al, ; Kagita Sailaja, Rao, Rao, & Vishnupriya, ). Similar results with our findings were clearly described regarding increased risk of CML for the GSTM1/null genotype by Bhat et al (), Lordelo et al () and Al‐Achkar et al (). In contrast, several studies suggested that GSTM1 may not be predisposing factor for CML risk (Taspinar et al, ; Weich et al, ).…”

Section: Discussionsupporting

confidence: 93%

Influence of glutathione S‐transferases (GSTM1, GSTT1, and GSTP1) genetic polymorphisms and smoking on susceptibility risk of chronic myeloid leukemia and treatment response

Rostami

Assad

Ghadyani

et al. 2019

Molec Gen & Gen Med

View full text Add to dashboard Cite

Background Glutathione S‐transferases (GSTs) polymorphisms may impact on chronic myeloid leukemia (CML) risk or heterogeneous responses to Imatinib mesylate (IM). The aim of this study was to evaluate the correlation between GSTs polymorphisms and CML risk, treatment response. Methods We genotyped GSTM1, GSTT1 null deletion polymorphisms, and GSTP1 Ile105Val polymorphism by PCR methods and BCR‐ABL transcripts were analyzed by qRT‐PCR in 104 CML patients and 104 sex‐ and age‐matched healthy individuals. Results Individual analysis showed significant association of GSTM1 ( p = 0.008; OR = 0.46; 95% CI: 0.26–0.82) and GSTP1 genes ( p = 0.04; OR = 1.56; 95% CI: 1.016–2.423) with CML risk. The combined analysis indicated that GSTM1 null/GSTT1 present, GSTM1‐null/GSTP1M*(AG/GG) as well as GSTT1 present/ GSTP1M* genotype were associated with CML risk (ORg(‐):2.28; 95% CI: 1.29–4.04; ORgg: 2.85; 95% CI: 1.36–5.97; OR(‐)g: 1.75; 95% CI: 0.99–3.06, respectively). The proportion of CML cancer attributable to the interaction of smoking and GSTM1 null, GSTT1null, and GSTP1 M* was 42%, 39%, and 13%, respectively. Patients with GSTM1‐null and GSTP1 AG/GG genotype had significantly a lower rate of MMR achievement ( p = 0.00; p = 0.009 respectively). Event‐free survival (EFS) percentage was similar between GSTM1 null and GSTM1 present patients ( p = 0.21). Conclusion Our study suggests the influence of GSTM1 and GSTP1 polymorphisms on CML risk and treatment response. The interaction between GSTs polymorphisms and smoking plays a significant role on CML susceptibility.

show abstract

Section: Discussionsupporting

confidence: 93%

Influence of glutathione S‐transferases (GSTM1, GSTT1, and GSTP1) genetic polymorphisms and smoking on susceptibility risk of chronic myeloid leukemia and treatment response

Rostami

Assad

Ghadyani

et al. 2019

Molec Gen & Gen Med

View full text Add to dashboard Cite

show abstract

“…Tobacco appears to be a risk factor (Balasubramaniam et al, 2013). and null genotypes of both GSTM1 and GSTT1 genes may confer elevated risk of chronic myeloid leukaemia (Bhat et al, 2012), implying carcinogen involvement. It is of clear intest that earlier studies of breast cancer showed highest incidences where pollution was highest, including Pavlodar (Bilyalova et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

Epidemiological Assessment of Leukemia in Kazakhstan, 2003-2012

Igissinov

Kulmirzayeva²,

Moore³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Cancer is a major health problem facing the entire world, and Kazakhstan is not the exception. The aim of this study was to present an epidemiological assessment of leukemia in the population of Kazakhstan during 2003-2012. This descriptive and retrospective study was based on data obtained from all oncological organizations of the whole country. Age standardized incidence rates per 100,000 population for leukemia were calculated. Totally, 6,741 new cases of leukemia were registered in Kazakhstan during the 10 year period. The mean age of patients with leukemia was 48.5. The ASRs for leukemia among men and women were 5.3 and 3.6, respectively (p<0.001). In conclusion, our results showed a high incidence rate of leukemia in Kazakhstan, especially in the north of the country. The incidence of leukemia was significantly higher in males and increased with age. Determining and controlling important risk factors of leukemia may lead to decrease in its burden.

show abstract

“…A number of studies reported that for CML, percentage of male is more than female (Bhat et al, 2012;Chavan et al, 2006;Irfan and Bhurgri, 2009;Usmani et al, 2009) and also the mean age for the patients is around between 40 to 50 years (Chavan et al, 2006;Irfan and Bhurgri, 2009;Bhat et al, 2012) that our study confirmed these results, but in other study (Usman et al, 2007), the median age at time of diagnosis was 33 years. These results show that percentage of males is more than females for CML and also the mean age and median age at diagnosis for the patients in majority of studies is around 40-50 years.…”

Section: Discussionmentioning

confidence: 99%

“…The known genetic abnormality associated with CML is the condition known as Philadelphia chromosome, which occurs as a result of reciprocal translocation between chromosome 9 and 22 leading to juxta-position of BCR-ABL gene (Bhat et al, 2012).…”

Section: Discussionmentioning

confidence: 99%

Treatment and Survival in Patients with Chronic Myeloid Leukemia in a Chronic Phase in West Iran

Payandeh

Sadeghi²,

Sadeghi³

2015

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: CML includes 30% of all leukemias, and occurs from childhood to old age. The present study was a retrospective analysis of chronic phase CML patients registered to a Hematology Clinic in Kermanshah, Iran, with checking of treatment options. Materials and Methods: Between 2002 and 2014, 85 CML patients referred to our hematology clinic were enrolled in our study. We surveyed age, sex, B-symptoms, splenomegaly, Sokal score, Hasford score, treatment and survival in all patients. Philadelphia chromosome analysis was conducted for each patient by conventional cytogenetics. We compared treatment in the patients with three drugs, imatinib, hydroxyurea (HU) and interferon alpha (IFN-α). Results: The mean age of the patients at diagnosis was 47.5±14.5 years (range, 23-82 years), with 43 (50.6%) being male. Some 13 (15.3%) were referred to our clinic for the first time with B-symptoms and 44 patients (51.8%) had splenomegaly. The Sokal score for 77 (90.6%) was low, 4 (4.7%) was intermediate and 4(4.7%) was high, but Hasford (Euro) scores for all patients were low. The 5-year survival rate for treated patients with imatinib, imatinib plus HU and imatinib plus HU plus IFN-α was 90.5%, 81.1% and 55.6%, respectively Conclusions: The results show that imatinib therapy alone provides better survival in CML patients compared to HU or IFN-α. Combinations of IFN-α and/or HU with imatinib probably reduce survival.

show abstract

Polymorphic Variation in Glutathione-S-transferase Genes and Risk of Chronic Myeloid Leukaemia in the Kashmiri Population

Cited by 31 publications

References 26 publications

Influence of glutathione S‐transferases (GSTM1, GSTT1, and GSTP1) genetic polymorphisms and smoking on susceptibility risk of chronic myeloid leukemia and treatment response

Influence of glutathione S‐transferases (GSTM1, GSTT1, and GSTP1) genetic polymorphisms and smoking on susceptibility risk of chronic myeloid leukemia and treatment response

Epidemiological Assessment of Leukemia in Kazakhstan, 2003-2012

Treatment and Survival in Patients with Chronic Myeloid Leukemia in a Chronic Phase in West Iran

Contact Info

Product

Resources

About